• Pre-exposure vaccination:
    • IM 1mL IM (deltoid region) x3 doses
    • Administer on days 0, 7 and 21 or 28
  • Post-exposure vaccination:
    • Unimmunized:
      • IM 1ml x5 doses
      • Administer on days 0, 3, 7, 14 and 28 in conjunction with administration of human rabies immune globulin (HRIG) on day 0
      • HRIG: 20 IU/kg
    • Immunized:
      • IM 1mL x2 doses on days 0 and 3

Injection: 2.5 IU

Vaccine

For HRIG, if anatomically feasible, the full dose should be infiltrated around and into the wound(s), and any remaining volume should be administered IM at an anatomical site distant from vaccine administration

The exact mechanism of action is unknown but it is thought to induce antibody formation

  • Injection site reaction
  • Influenza-like symptoms
  • Myalgia
  • Headache
  • Malaise
  • Arthralgia
  • Dizziness
  • Lymphadenopathy
  • Nausea
  • Rash
  • Hypersensitivity to drug/class/components (pre-exposure prophylaxis use)
  • Intradermal use
  • SC use
  • Chloroquine
  • Interferon gamma
  • Belimumab

                                   Drug Status

Availability Prescription only
Pregnancy Can be used
Breastfeeding Can be used
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Abhayrab FDC Injection 1D Human Biologicals Surgipharm Ltd
Indirab FDC Injection 1D Bharat Biotech Pharma Specialities
Rabies Vaccine FDC Injection 1D Serum Institute Sai Pharma
Speeda FDC Injection 1D Liaoning Cheng Medisel Kenya
Vaxirab N FDC Injection 1D Cadila Healthcare Cadila Healthcare
Verorab FDC Injection 1D Sanofi Pasteur Ressourcethica Kenya